Leading the way to safer medication
 Crosscheck  Recommender

Bosutinib

Brand names: BOSULIF

Therapeutic Indications

Bosutinib is indicated for:

Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)

Irrespective of gender only Adults (18 years old or older)

Bosutinib is indicated for the treatment of adult patients with:

  • newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).
  • CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 400-500 mg once daily

Contraindications

Active ingredient Bosutinib is contraindicated in the following cases: